AIM: £4.81 (+0.15) | Nasdaq: $34.13 (+0.85)
Search
  • EN
  • 简
  • 繁
  • About Us
    • Overview
    • Corporate Information
    • Board of Directors
    • Senior Management
    • Contact Us
  • Innovation Platform
    • Overview
    • R&D Approach
    • Our Pipeline
    • Expanded Access
    • Key Corporate Partnerships
    • Innovation News
  • Commercial Platform
    • Overview
    • Competitive Advantages
    • Prescription Drugs
    • Consumer Health
    • Commercial Platform News
  • News & Presentations
    • Recent News
    • All RNS & Press Releases
    • Presentations & Publications
  • Financial Results
    • Overview
    • Chairman's Statement
    • Financial Highlights
    • Financial Reports
    • SEC Filings
  • Shareholder Information
    • Overview
    • Events, Circulars & Forms
    • Share Price & Chart
    • Major Shareholders
    • Analyst Coverage
    • Dual-listing FAQs
    • Information for Shareholders
    • Warning to Shareholders
    • Terms of Reference & Policies
    • AIM Rule 26
  • Careers
  • EN
  • 简
  • 繁
  • About Us
    • Overview
    • Corporate Information
    • Board of Directors
    • Senior Management
    • Contact Us
  • Innovation Platform
    • Overview
    • R&D Approach
    • Our Pipeline
    • Expanded Access
    • Key Corporate Partnerships
    • Innovation News
  • Commercial Platform
    • Overview
    • Competitive Advantages
    • Prescription Drugs
    • Consumer Health
    • Commercial Platform News
  • News & Presentations
    • Recent News
    • All RNS & Press Releases
    • Presentations & Publications
  • Financial Results
    • Overview
    • Chairman's Statement
    • Financial Highlights
    • Financial Reports
    • SEC Filings
  • Shareholder Information
    • Overview
    • Events, Circulars & Forms
    • Share Price & Chart
    • Major Shareholders
    • Analyst Coverage
    • Dual-listing FAQs
    • Information for Shareholders
    • Warning to Shareholders
    • Terms of Reference & Policies
      • Audit Committee – Terms of Reference
    • AIM Rule 26
  • Careers
Surufatinib approval In China and initiation of Chi-Med's first U.S. NDA submission Watch Interview
Corporate Presentation Building a global science-focused biopharma from an established base in China Download Presentation
Surufatinib at ESMO 2020 and SANET-ep & SANET-p results in The Lancet Oncology Learn More
The Lancet Oncology: Osimertinib plus Savolitinib in EGFRm+, MET-amplified NSCLC Read Abstract
AstraZeneca & Chi-Med Harnessing the power of Chinese scientific innovation Learn More

Latest News


Innovation Platform | 14 Jan 2021Chi-Med Highlights Savolitinib Clinical Data to be Presented at Virtual WCLC
Innovation Platform | 11 Jan 2021Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases
Innovation Platform | 30 Dec 2020Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors
Innovation Platform | 29 Dec 2020Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors
Group | 22 Dec 2020Chi-Med to Present at the 39th Annual JP Morgan Healthcare Conference

Current Share Price


London AIM:HCM
£4.81+0.15 | 22 Jan 2021 | 16:35
Nasdaq AIM:HCM
US$34.13+0.85 | 22 Jan 2021 | 16:00

Note: 1 Nasdaq share = 5 AIM shares

Latest Presentations


9 Jan 2021 Corporate Presentation
5 Dec 2020 ASH2020: Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral PI3Kδ Inhibitor, in Chinese Patients with Relapsed/Refractory Lymphomas
21 Sep 2020 The Lancet Oncology: Surufatinib SANET-p phase 3 study

Latest Reports


Interim Report 2020
EN
Annual Report 2019 (with Form 20-F)
EN
Interim Report 2019
EN

Share conversions between AIM & Nasdaq

Mailing list sign-up

Analyst Coverage

The leading China-based innovator


Our Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.
Learn More

A powerful commercial network in China


Our Commercial Platform manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.
Learn More

 
  • Contact Us
  • Disclaimer
  • Privacy Policy
© 2021 Hutchison China MediTech Limited